© 2024 by Daré Bioscience | Daré Bioscience® is a registered trademark of Daré Bioscience, Inc.
The FDA has cleared our investigational new drug (IND) application for DARE-VVA1
We are excited to announce that the FDA has cleared our investigational…
Pivotal Phase 3 clinical study of Ovaprene Announced
We are excited to announce the commencement of our pivotal Phase…
Congratulations to our President and CEO, Sabrina Johnson, on being named to the SDBJ’s list of influential businesspeople…
Congratulations to our President and CEO, Sabrina Johnson, on…
San Diego Business Journal: Daré Progresses Women-Centric Drug Pipeline (Subscription required)
San Diego Business Journal: Daré Progresses Women-Centric Drug…
Daré Bioscience Placed #1 in the Small Company Category of the San Diego Business Journal’s “2023 Best Places to Work” (Subscription required)
Daré Bioscience Placed #1 in the Small Company Category of the…
LifeLines Podcast: Advocating For Equity in Women’s Health and Building a Pipeline of Differentiated Treatment Options
LifeLines Podcast: Advocating For Equity in Women’s Health…
Sabrina Martucci Johnson, Daré’s President & CEO, Named as One of FiercePharma’s Most Influential People in Biopharma in 2023
Sabrina Martucci Johnson, Daré's President & CEO, Named…
PharmaVoice: Leaders wave a magic wand at pharma’s thorniest issues
PharmaVoice: Leaders wave a magic wand at pharma’s thorniest…
Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion (Subscription required)
Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity,…
San Diego Business Journal: Sabrina Martucci Johnson, Daré’s President and CEO, Named as of San Diego’s Top 50 Most Influential Women Over 50
San Diego Business Journal: Sabrina Martucci Johnson, Daré's…
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances (Subscription required)
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic…
Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends (Subscription required)
Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical…
HealthLeaders: Daré Bioscience CEO Drives Culture of Transformation in Women’s Health
HealthLeaders: Daré Bioscience CEO Drives Culture of Transformation…
PharmaVoice: What’s top of mind for industry execs at JPM?
PharmaVoice: What’s top of mind for industry execs at JPM?
HealthLeaders: Increased Contraceptive Education Can Help Manage Impact of Roe vs. Wade
July 22, 2022
Endpoints News: ‘We will continue to fight’: Contraceptive companies remain hopeful after House passes bill
July 22, 2022
Endpoints News: After abortion ruling, biotechs behind novel contraceptives say tide is turning on insurance coverage
July 19, 2022
FierceBiotech: Biotech’s women leaders decry US abortion bans: ‘We will not stand by silently’
July 5, 2022
FierceBiotech: ‘Organize. Align’: Women in biotech see Roe v. Wade ruling as a call to action
July 11, 2022